Artal Group S.A. Mersana Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $2.51 Million - $7.77 Million	813,767 Added 36.73%	3,029,555 $9.97 Million
Q1 2023 May 12, 2023	BUY	$4.0 - $7.02 $63,152 - $110,831	15,788 Added 0.72%	2,215,788 $9.11 Million
Q1 2022 May 12, 2022	BUY	$3.74 - $6.63 $3.74 Million - $6.63 Million	1,000,000 Added 83.33%	2,200,000 $8.78 Million
Q4 2020 Feb 11, 2021	BUY	$16.84 - $27.59 $3.37 Million - $5.52 Million	200,000 Added 20.0%	1,200,000 $31.9 Million
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $3.24 Million - $5.14 Million	200,000 Added 25.0%	1,000,000 $18.6 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $4.19 Million - $18.7 Million	800,000 New	800,000 $18.7 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.